STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 30 minutes later, on .
Signal breakdown
CurrentWire ranked this story 62.3 of 100 in the snapshot this page was rendered from.
- Freshness
- 32.8 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 32.8 of 35. How each signal is calculated.
Filed under Health · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Novo Nordisk (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.